Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Harold Bernstein Sells 16,141 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,141 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $26.93, for a total value of $434,677.13. Following the transaction, the chief marketing officer directly owned 16,141 shares in the company, valued at $434,677.13. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Friday, September 4th, Harold Bernstein sold 9,705 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.22, for a total transaction of $254,465.10.
• On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total transaction of $134,965.89.
• On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total transaction of $135,155.82.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total transaction of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62.

Maze Therapeutics Stock Down 0.8%

Shares of NASDAQ:MAZE traded down $0.22 during mid-day trading on Friday, hitting $26.43. 633,043 shares of the company traded hands, compared to its average volume of 665,641. The stock has a 50-day moving average price of $27.00 and a two-hundred day moving average price of $28.23. Maze Therapeutics, Inc. has a 12-month low of $21.95 and a 12-month high of $53.65. The stock has a market cap of $1.47 billion, a P/E ratio of -10.49 and a beta of 2.16. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). On average, equities research analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Analysts Set New Price Targets

MAZE has been the subject of several research reports. Wedbush restated an “outperform” rating and set a $48.00 price target on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Maze Therapeutics in a research report on Thursday, September 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. BTIG Research reissued a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Finally, Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $63.40.

Hedge Funds Weigh In On Maze Therapeutics

Several large investors have recently modified their holdings of MAZE. Frazier Life Sciences Management L.P. lifted its stake in shares of Maze Therapeutics by 10.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after buying an additional 465,641 shares in the last quarter. TRV GP IV LLC bought a new stake in Maze Therapeutics during the 2nd quarter valued at $133,502,907. ARCH Venture Management LLC purchased a new stake in shares of Maze Therapeutics during the second quarter worth $122,983,582. BlackRock Inc. purchased a new stake in shares of Maze Therapeutics during the second quarter worth $104,525,000. Finally, Jupiter Topco LLC bought a new position in shares of Maze Therapeutics in the second quarter worth $101,764,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.